Cytokinetics CEO Robert I. Blum Sells Shares, Exercises Options

What Happened

• Robert I. Blum, President & CEO (and director) of Cytokinetics (CYTK), exercised 7,500 stock options and sold shares in transactions on Sept 14–15, 2026. He exercised 7,500 options at $10.60 ($79,500) and sold those 7,500 shares the same day at $73.44 for $550,800. Separately, 97,926 shares that were transferred to The Bridget Blum 2026 Irrevocable Trust were sold on Sept 15 at $69.33 for $6,789,210. There were also gifts/transfers of 1,350 shares and transfers to the 2026 trust reported the same period. Total reported sale proceeds around $7.34M.

Key Details

• Transaction dates and prices:
  • 2026-09-14: Exercised 7,500 options at $10.60 (cost $79,500) — footnote: 10b5-1 plan.
  • 2026-09-14: Sold 7,500 shares at $73.44 (proceeds $550,800) — footnote: 10b5-1 plan.
  • 2026-09-14: Gifted 1,350 shares (charitable gift).
  • 2026-09-14: Transferred 97,926 shares to The Bridget Blum 2026 Irrevocable Trust (reporting person is co‑trustee; disclaims beneficial ownership).
  • 2026-09-15: The Bridget Blum 2026 Irrevocable Trust sold 97,926 shares at $69.33 (proceeds $6,789,210); reporting person disclaims beneficial ownership in those trust shares/proceeds.
• Approximate total sale proceeds reported: ~$7,340,010.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes: multiple entries state transactions were pursuant to a Rule 10b5‑1 trading plan (options exercise and sale), charitable gift, and transfers/sales by an irrevocable trust (reporting person disclaims beneficial ownership).
• Filing timeliness: Report filed 2026-09-15 for transactions on 2026-09-14/15 — appears timely.

Context

• The 7,500-option exercise followed by same‑day sales is effectively a cashless exercise (exercise + immediate sale). Footnotes indicate the exercise and some sales were executed under a prearranged 10b5‑1 plan, which is a rule‑based trading plan often used to avoid insider trading issues.
• The large ~97,926‑share sale was completed by an irrevocable trust to which shares were transferred; gifts and trust transfers are not direct market sentiment from the insider and the filer disclaims beneficial ownership of the trust shares per the footnotes.
• Retail investors should note purchases generally carry more informational weight than routine, plan-driven sales; here most activity appears to be option exercise and preplanned or trust-driven sales rather than an open-market, discretionary sale by the CEO.